Gilead Rises with Acquisition, Novo Nordisk GLP1 Drops, Domino's Cooks
Feb 23, 2026
A big biotech takeover shakes up cancer drug pipelines with a nearly $7.8B deal. Results from the GLP-1 trials spark sharp market moves after a head-to-head weight‑loss comparison. Pizza chain sales and earnings momentum drive talks of restaurant-sector resilience and expansion.
04:48
forum Ask episode
web_stories AI Snips
view_agenda Chapters
auto_awesome Transcript
info_circle Episode notes
insights INSIGHT
Gilead Expands Into Cancer With Arcellx Buyout
Gilead's acquisition of Arcellx accelerates its shift from antivirals into oncology and immunotherapy.
Gilead pays $115 per share plus a $5 contingent payment, nearly doubling Arcellx's predeal price and leveraging its existing 11.5% stake.
insights INSIGHT
Novo Nordisk Falls After Weaker Obesity Drug Results
Novo Nordisk's next-generation obesity shot underperformed versus Lilly's tirzepatide, dealing a severe market blow.
Trial showed 20.2% weight loss for CagriSema versus 23.6% for tirzepatide, sending Novo shares down about 16.5% in Copenhagen.
question_answer ANECDOTE
Host Praises Domino's App And Neighborhood Presence
Unknown Host shares a personal view that Domino's app and convenience drive repeat orders from consumers.
He praises Domino's one-click app and mentions passing a local store and smelling pizza, highlighting everyday brand familiarity.
Get the Snipd Podcast app to discover more snips from this episode
Today's biggest winners and losers in the stock market.
On this episode of Stock Movers:
- Gilead Sciences Inc. agreed to buy US cancer-focused biotech Arcellx Inc. for as much as $7.8 billion as it seeks to boost its drug pipeline. Gilead, which owns 11.5% of Arcellx’s outstanding stock, will pay $115 per share in cash, with a contingent payment of $5 per share dependent on future sales, it said Monday. The price is almost double Arcellx’s Friday closing price. Shares of Arcellx rose as much as 78% to $114.18 in premarket trading in New York, while Gilead’s stock slipped about 0.6%.
- Novo Nordisk A/S’s next-generation obesity shot delivered less weight loss than Eli Lilly & Co.’s rival blockbuster in yet another blow to the Danish company’s attempts to regain lost ground in the weight-loss market. People treated with a standard dose of Novo’s CagriSema in a trial achieved 20.2% weight loss after 84 weeks, compared with 23.6% for Lilly’s tirzepatide. Novo’s shares plunged as much as 16.5% in Copenhagen on Monday, while Lilly shares rose as much as 4.2% in premarket US trading.
- Domino's Pizza posted another quarter with strong comparable-sales growth and new restaurant openings, which sent the stock higher Monday. Still, shares have been trading at their lowest levels in more than two years as investors remain cautious about the restaurant sector. For the fourth quarter ended in December, the pizza chain grew its net revenue by 6.4% from a year ago to $1.54 billion, beating Wall Street's consensus expectations of $1.52 billion. Earnings came in at $5.35 per share, up 9.4% from a year earlier, but slightly below the expected $5.38, the company said Monday.
Stock Movers